ABIONYX Pharma's CER-001 on Fast Track After Successful FDA Pre-IND Meeting
ABIONYX Pharma completes pre-IND meeting with FDA, plans IND filing for apoA-I-based drug, advancing treatments for sepsis and critical care.
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible) is a
biotech firm focused on developing innovative therapies using the world's only
natural recombinant apoA-I, announced today that it has successfully completed
a pre-IND (Investigational New Drug Application) meeting with the US FDA and
has received feedback supporting an IND filing for its candidate drug.
This is a crucial endorsement of the project's quality and a
major move towards including American study centres in upcoming clinical
trials. ABIONYX Pharma plans to submit an IND application to the US authorities
in the next few months.ABIONYX Pharma is a cutting-edge biotech company
dedicated to creating innovative treatments for diseases that currently have no
effective or existing therapies, including rare conditions.
Utilizing their deep expertise in lipid science and a unique
apoA-I-based technology platform, the company accelerates the development of
new therapeutics. ABIONYX Pharma is focused on significantly enhancing
treatment outcomes for Sepsis and critical care patients.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Mehr aus Pharma News
Alle Beiträge →
Ab Science überarbeitet Studienzeitpläne nach drei GCP-Inspektionen
Novo Nordisk unterzeichnet einen $2,6B-Deal mit Hengrui für orales GLP-1
Discussion